IMNM

Business Context and Reporting Period

Company: Immunome, Inc. (IMNM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2024
Business Overview: Immunome is a biotechnology company focused on developing targeted oncology therapies. Its pipeline includes one clinical asset, AL102 (a gamma secretase inhibitor in Phase 3 for desmoid tumors), and two preclinical assets: IM-1021 (ROR1 ADC) and IM-3050 (FAP-targeted radioligand therapy). The company operates as a single segment and is classified as an emerging growth company and smaller reporting company.

Key Financial Metrics

Share Count: 60,422,062 shares outstanding as of September 30, 2024.

Material Changes vs. Prior Period

• Revenue Decline: Collaboration revenue decreased 18% quarter-over-quarter (QoQ) to $2.9 million and 38% year-over-year (YoY) for the nine months to $6.3 million, primarily due to reduced R&D activities allocated to the AbbVie collaboration.
• Significant Expense Increase: Total operating expenses surged to $53.4 million for the quarter (from $8.2 million in Q3 2023) and $229.1 million for the nine months (from $25.1 million in 2023). This was driven by a one-time $125.0 million charge for in-process research and development (IPR&D) assets acquired with no alternative future use.
• Net Loss Expansion: Net loss widened significantly to $47.1 million for the quarter and $212.7 million for the nine months, compared to $4.3 million and $14.2 million in the prior year periods, respectively.
• Liquidity Improvement: Cash and cash equivalents increased from $98.7 million at year-end 2023 to $155.6 million at September 30, 2024, bolstered by a $215.4 million net proceeds from a February 2024 public offering.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($240.1 million total) to fund operations for at least 12 months from the filing date. Additional capital will be required thereafter.
• Strategic Transactions:
  • Ayala Acquisition: Acquired AL102 (Phase 3 desmoid tumor asset) in March 2024 for ~$71.3 million (cash and stock).
  • Zentalis Acquisition: Acquired ROR1 ADC assets in October 2024 (subsequent event) via stock issuance, terminating the prior license agreement.
  • BMS Amendment: Issued stock to Bristol-Myers Squibb in August 2024 to amend a license agreement.
• Key Risks:
  • Capital Requirements: Significant additional funding is needed to advance clinical trials (AL102) and preclinical programs (IM-1021, IM-3050). Failure to raise capital could force delays or termination of programs.
  • Development Uncertainty: No products are approved; success depends on clinical trial outcomes and regulatory approvals, which are uncertain and costly.
  • IPR&D Volatility: Future results may be materially impacted by the timing and accounting treatment of asset acquisitions and license agreements.

Investor Verification Checklist

• Cash Runway: Verify the 12-month liquidity estimate against current burn rates, especially given the high operating expenses driven by asset acquisitions.
• AL102 Phase 3 Status: Confirm enrollment completion and expected topline data release (H2 2025) for the RINGSIDE Part B trial.
• Subsequent Events: Review the October 2024 Zentalis Asset Purchase Agreement details and the impact of the stock issuance on dilution.
• IPR&D Accounting: Understand the $125 million non-cash charge and its impact on future comparability of operating expenses.
• Collaboration Revenue: Monitor the AbbVie collaboration revenue recognition, which is dependent on R&D service performance and may fluctuate.